Despite Johnson & Johnson reporting better-than-expected Q1 2025 adjusted EPS of $2.77 and revenue of $21.9 billion, shares fell marginally on Apr. 15 due to concerns over declining Stelara sales ...

Wall Street’s excessive focus on vaccine sales has created an opportunity for investors to buy J&J shares at a discount. ... Johnson & Johnson’s Stock Deserves a Booster.

Johnson & Johnson (NYSE: JNJ) is an iconic U.S. healthcare giant. There are a lot of positives with J&J, as it is more ...

Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2 per share in its forthcoming report, representing a decline of 12.7% year over year.

Johnson & Johnson reported third-quarter results before the stock market opened on Tuesday, Oct. 15. Johnson & Johnson raised its sales outlook but lowered its guidance range for adjusted earnings.

Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance Provided by Dow Jones Jan 22, 2025, 4:45:00 PM. By Ciara Linnane .

Wall Street Might Be Missing This Key to Growth at Johnson & Johnson. By Jason Hawthorne – Jul 29, 2021 at 6:09AM Key ... Most shareholders in Johnson & Johnson (JNJ-0.76%) ...

Investors hate uncertainty, goes the old Wall Street cliché. The saying is especially apt when a blue-chip stock known for being a safe investment suddenly becomes a source of worry.

Wall Street's average bonus in 2022 was $176,700, down from $240,400 the year before, the comptroller's office found. "The last two years were pretty clear — one year was straight up and one was ...

Although Johnson & Johnson has lagged behind the SPX over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.